Heartview Approved as Clinical Trial Site
Posted 4/13/11 (Wed)
Heartview has gained approval as a clinical trial site by the National Institute of Drug Abuse. NIDA’s mission is to “lead the nation in bringing the power of science to bear on drug abuse and addiction. NIDA conducts cutting edge research and works to disseminate the results to improve prevention, treatment and policy as it relates to drug abuse and addiction.
As a clinical trial site, Heartview may be chosen to test new treatment medications or other new innovations in the addiction field. Appropriate patients will be given the opportunity to participate, if they so choose. Specific, anonymous, study data will be collected, and reported to NIDA.
A recent clinical trial conducted by NIDA at other centers throughout the country showed that Buprenorphine is significantly more successful in assisting patients with withdrawal and maintenance from opioid addiction than an alternative medication known as Clonidine. Heartview recently started a Buprenorphine treatment program, and it is largely through the efforts of NIDA clinical trials that the best treatment enhancements are identified for providers such as Heartview.